Category: Federal Forum Posters
Purpose: Safety of quetiapine doses less 150mg/day have not been well studied. Metabolic side effects have been noted to occur with indicated doses of quetiapine such as weight gain, hypertension, increase in blood sugar, and increase in cholesterol. Non-metabolic side effects may be cause with low dose quetiapine such as restless leg syndrome, daytime sedation, dry mouth, and hepatotoxicity. The purpose of this study is to determine the metabolic impact and safety of low dose quetiapine.
Methods: This study has undergone Intern Institutional Review Board approval. All data will come from electronic chart review and will include information gathered via a standardized data collection form. All patients included in the study must be followed by Dorn VA on an outpatient basis and identified based on the inclusion and exclusion criteria defined above between April 1, 2008 and April 1, 2018. Patients will be included if they received an outpatient prescription for quetiapine with a total daily dose of less than 150mg/day between the dates of April 1, 2008 and April 1, 2018 with cumulative exposure greater than 3 months and if they had metabolic parameters documented within 1 year before initiation of quetiapine and within 12 months of discontinuation. Patients will be matched according to baseline characteristics in dosing groups of 1-25mg/day, 26-50mg/day, 51-100mg/day, and 101-150mg/day. Metabolic parameters will include weight, BMI, total cholesterol, HDL, LDL, triglycerides, and HbA1c.
Melanie Routhieaux– P4 Pharmacy Student, Presbyterian College School of Pharmacy, Clinton, SC